Jazz Pharmaceuticals Short Interest Ratio and Short Volume

Jazz Pharmaceuticals (NASDAQ:JAZZ) Short Interest Frequently Asked Questions

What is Jazz Pharmaceuticals' current short interest?

Short interest is the volume of Jazz Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of December 31st, investors have sold 4,440,000 shares of JAZZ short. 7.44% of Jazz Pharmaceuticals' shares are currently sold short. Learn More on Jazz Pharmaceuticals' current short interest.

What is a good short interest ratio for Jazz Pharmaceuticals?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. Jazz Pharmaceuticals currently has a short interest ratio of 7.0. Learn More on a good short interest ratio for Jazz Pharmaceuticals

Which institutional investors are shorting Jazz Pharmaceuticals?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Jazz Pharmaceuticals: Cutler Group LP, Jefferies Group LLC, BNP Paribas Arbitrage SA, Jane Street Group LLC, Two Sigma Investments LP, UBS Group AG, Citadel Advisors LLC, CSS LLC IL, PEAK6 Investments LLC, Wolverine Trading LLC, HAP Trading LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for Jazz Pharmaceuticals?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 7.44% of Jazz Pharmaceuticals' floating shares are currently sold short.

Is Jazz Pharmaceuticals' short interest increasing or decreasing?

Jazz Pharmaceuticals saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 4,440,000 shares, an increase of 0.7% from the previous total of 4,410,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Jazz Pharmaceuticals' float size?

Jazz Pharmaceuticals currently has issued a total of 61,470,000 shares. Some of Jazz Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Jazz Pharmaceuticals currently has a public float of 59,660,000 shares.

How does Jazz Pharmaceuticals' short interest compare to its competitors?

7.44% of Jazz Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sub-industry of "pharmaceuticals" compare to Jazz Pharmaceuticals: Johnson & Johnson (0.00%), Pfizer Inc. (0.00%), AbbVie Inc. (0.94%), Eli Lilly and Company (0.60%), Merck & Co., Inc. (0.92%), Bristol-Myers Squibb (0.92%), Zoetis Inc. (0.43%), Royalty Pharma plc (1.63%), Horizon Therapeutics Public Limited (1.64%), and Perrigo Company plc (5.02%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: S&P Global Inc. ($9.39 billion), Advanced Micro Devices, Inc. ($9.08 billion), Charter Communications, Inc. ($7.16 billion), Palo Alto Networks, Inc. ($4.05 billion), Lucid Group Inc ($3.43 billion), Wayfair Inc. ($3.11 billion), Rivian ($3.05 billion), Datadog, Inc. ($2.76 billion), Zscaler, Inc. ($2.55 billion), and Etsy, Inc. ($1.99 billion). View all of the most shorted stocks.

What does it mean to sell short Jazz Pharmaceuticals stock?

Short selling JAZZ is an investing strategy that aims to generate trading profit from Jazz Pharmaceuticals as its price is falling. Jazz Pharmaceuticals' stock is trading down $2.37 today. To short Jazz Pharmaceuticals stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Jazz Pharmaceuticals will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Jazz Pharmaceuticals?

A short squeeze for Jazz Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of JAZZ, which in turn drives the price of the stock up even further.

How often is Jazz Pharmaceuticals' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including JAZZ, twice per month. The most recent reporting period available is December, 31 2021.